Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States.
about
Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base.Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a role?Residence proximity to benzene release sites is associated with increased incidence of non-Hodgkin lymphoma.Racial differences in mantle cell lymphoma in the United States.The diffusion of docetaxel in patients with metastatic prostate cancerClinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center.Survival disparities by insurance type for patients aged 15-64 years with non-Hodgkin lymphomaDisease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma.US trends in survival disparities among adolescents and young adults with non-Hodgkin lymphoma.Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma.Racial differences in chronic lymphocytic leukemia. Digging deeper.Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma.Trends and Predictors of Chemotherapy Use among Thyroid Cancer Patients in the National Cancer Database (2004-2013).Insights on practice variations in the management of lymphoma and leukemia.Racial and Ethnic Disparities in Hematologic Malignancies.Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D.Relations Between Residential Proximity to EPA-Designated Toxic Release Sites and Diffuse Large B-Cell Lymphoma Incidence.Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database.Nationwide Statistical Analysis of Lymphoid Malignancies in Korea.Disparities in survival by insurance status in patients with Hodgkin lymphoma.What is the optimal management of early-stage low-grade follicular lymphoma in the modern era?Impact of delays in definitive treatment on overall survival: a National Cancer Database study of patients with Hodgkin lymphoma.Disparities in receipt of radiotherapy and survival by age, sex and ethnicity among patients with stage I diffuse large B-cell lymphoma.Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?Insurance status is related to diffuse large B-cell lymphoma survival.Older patients with early-stage diffuse large B-cell lymphoma: the role of consolidation radiotherapy after chemoimmunotherapy.Improving the accuracy in prognosis for Burkitt lymphoma patients.
P2860
Q30978936-7A6768CD-C3CA-4713-A6BF-BC8725668244Q33573780-0F460CE2-7189-4D5E-A943-41D154245389Q34118021-B57CD768-202A-4330-A0ED-56E1A7ECB69DQ34410264-20F206FD-CEEA-43BC-8095-24789B1C7DF4Q35078581-4085F7A4-E104-4873-A87B-13D867C30402Q35382759-AA497111-D4D9-4040-9EC1-06D72C53F916Q35586706-D25751B9-7B48-46E4-AA5A-FBB1194E34EAQ35637806-C3E43404-C71D-4CEC-9BB3-D1763FDD53F4Q36015886-957E83EB-577C-41E0-8D98-4B656519C79CQ36074344-7A99248D-7832-4D3F-BCEE-F2925B04BA34Q37326806-7AA61612-9A23-418C-B7D6-3E99BC643D61Q37359378-8E87628C-5B57-48FC-931E-A4C06F801CBBQ37562871-ECF09E0C-ED7B-448A-9B24-0E641D9FC829Q38177354-4FDF538A-4C0E-4CE4-A4DC-A01F72CCDF3EQ38654981-B587B347-F19B-4771-A6C2-E92583B6F0D6Q38679176-81E76A69-7CAE-45B3-B95D-E4430B3F55A2Q38719277-7DF52BA3-608B-48F7-B3B5-F3D0114F119BQ39320244-EE0DC142-7DD9-4DB2-9065-23BB8ACCC9DEQ39372883-E5281841-58A8-41A5-81A7-97C565736D04Q40265830-8DDD14FF-1BB3-4EA3-A7D0-172CD5EB6A55Q40853433-FC77CAF3-89E8-46F2-95D2-BFA5D29C436AQ40870346-DCA072AF-5A46-4403-BC35-30DE12E023CCQ41355259-4DE2F8E8-4017-4A4D-9FDB-0E0B3C099F03Q44492875-61B40192-CF61-46BE-9F18-511601672300Q48207286-F1121D10-4D2B-4C77-A5AA-DEBD3623AEFEQ50132026-A1F43A10-A406-4C88-8EAB-C2DC2CDF4564Q53019638-BBEBF75A-ADA7-440C-B052-6BEA3C70ACEEQ54454234-48A93162-383E-4A88-B432-C9FC7648457C
P2860
Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Disparities in the early adopt ...... lymphoma in the United States.
@ast
Disparities in the early adopt ...... lymphoma in the United States.
@en
Disparities in the early adopt ...... lymphoma in the United States.
@nl
type
label
Disparities in the early adopt ...... lymphoma in the United States.
@ast
Disparities in the early adopt ...... lymphoma in the United States.
@en
Disparities in the early adopt ...... lymphoma in the United States.
@nl
prefLabel
Disparities in the early adopt ...... lymphoma in the United States.
@ast
Disparities in the early adopt ...... lymphoma in the United States.
@en
Disparities in the early adopt ...... lymphoma in the United States.
@nl
P2093
P2860
P1476
Disparities in the early adopt ...... lymphoma in the United States.
@en
P2093
Amy Y Chen
Christopher R Flowers
Elizabeth M Ward
Joseph Lipscomb
Loretta J Nastoupil
Otis W Brawley
Stacey A Fedewa
P2860
P304
P356
10.1158/1055-9965.EPI-12-0466
P577
2012-07-06T00:00:00Z